Texas Capital Bank Wealth Management Services Inc Takes Position in Cue Biopharma, Inc. $CUE

Texas Capital Bank Wealth Management Services Inc purchased a new stake in Cue Biopharma, Inc. (NASDAQ:CUE) in the 2nd quarter, HoldingsChannel reports. The fund purchased 22,881 shares of the company’s stock, valued at approximately $722,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd purchased a new position in Cue Biopharma during the 2nd quarter worth approximately $389,000. Stifel Financial Corp raised its stake in Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after purchasing an additional 50,000 shares during the period. BlackRock Inc. purchased a new stake in shares of Cue Biopharma in the second quarter valued at $1,824,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma in the third quarter worth $62,000. Institutional investors and hedge funds own 35.04% of the company’s stock.

Insider Activity at Cue Biopharma

In related news, CEO Shao-Lee Lin sold 18,258 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $28.62, for a total value of $522,543.96. Following the transaction, the chief executive officer owned 705,995 shares in the company, valued at approximately $20,205,576.90. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Michael Vincent Meluzio sold 5,628 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $30.09, for a total value of $169,346.52. Following the completion of the transaction, the vice president owned 48,961 shares in the company, valued at $1,473,236.49. This represents a 10.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 72,715 shares of company stock valued at $2,041,555. 14.56% of the stock is owned by corporate insiders.

Analyst Ratings Changes

CUE has been the topic of a number of research analyst reports. Wall Street Zen downgraded Cue Biopharma from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Cue Biopharma in a research note on Thursday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Cue Biopharma Trading Down 19.2%

CUE opened at $27.64 on Tuesday. The stock has a fifty day moving average price of $29.47 and a 200 day moving average price of $143.72. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50. The stock has a market cap of $116.09 million, a price-to-earnings ratio of -1.02 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last issued its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.The firm had revenue of $7.88 million during the quarter, compared to analyst estimates of $3.00 million.

Cue Biopharma Profile

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.